Results of a double-blind, placebo-controlled Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients with Critical Limb Ischemia

被引:226
作者
Powell, Richard J. [1 ]
Simons, Michael [2 ]
Mendelsohn, Farrel O. [3 ]
Daniel, George [4 ]
Henry, Timothy D. [5 ]
Koga, Minako [6 ]
Morishita, Ryuichi [7 ]
Annex, Brian H. [8 ]
机构
[1] Dartmouth Coll, Hitchcock Med Ctr, Dept Surg, Vasc Surg Sect, Lebanon, NH 03756 USA
[2] Dartmouth Coll, Hitchcock Med Ctr, Dept Med, Cardiol Sect, Lebanon, NH 03756 USA
[3] Princeton Heart & Vasc Ctr, Birmingham, AL USA
[4] John F Kennedy Med Ctr, Atlantis, FL USA
[5] Minneapolis Heart Inst Fdn, Minneapolis, MN USA
[6] AnGes Inc, Gaithersburg, MD USA
[7] Osaka Univ, Osaka, Japan
[8] Duke Univ, Med Ctr, Durham, NC USA
关键词
critical limb ischemia; angiogenesis; gene therapy; peripheral vascular disease; atherosclerosis;
D O I
10.1161/CIRCULATIONAHA.107.727347
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - The Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients With Critical Limb Ischemia (HGF-STAT trial) determined the effect of hepatocyte growth factor (HGF) plasmid on safety and limb tissue perfusion as measured by transcutaneous oxygen tension (TcPO(2)) in patients with critical limb ischemia (CLI). Methods and Results - Randomized patients with rest pain or ischemic ulcers and TcPO2 < 40 mm Hg and/or toe pressure < 50 mm Hg received placebo or HGF-plasmid intramuscular injection as follows: 0.4 mg at days 0, 14, and 28 (low dose); 4.0 mg at days 0 and 28 (middle dose); or 4.0 mg at days 0, 14, and 28 ( high dose). Patients were evaluated for safety, changes in TcPO(2) and ankle and toe pressure, amputation, and wound healing. Ninety-three of 104 treated patients were evaluated for safety (mean age 70 years, 63% male, 53% diabetic, 64% with tissue loss, mean ankle-brachial index 0.41, and mean toe pressure 26 mm Hg). Adverse events occurred in 86% of the patients, most of which were related to CLI or comorbid conditions and were not different between groups. TcPO(2) (mean +/- SE) increased at 6 months in the high-dose group (24.0 +/- 4.2 mm Hg, 95% CI 15.5 to 32.4 mm Hg) compared with the placebo (9.4 +/- 4.2 mm Hg, 95% CI 0.9 to 17.8), low-dose (11.1 +/- 3.7 mm Hg, CI 3.7 to 18.7 mm Hg), and middle-dose (7.3 +/- 4.8 mm Hg, CI -2.2 to 17.0 mm Hg) groups (ANCOVA P=0.0015). There was no difference between groups in secondary end points, including ankle-brachial index, toe-brachial index, pain relief, wound healing, or major amputation. Conclusions - Intramuscular injection of HGF plasmid was safe and well tolerated. Larger studies to determine whether HGF plasmid can improve wound healing and limb salvage in patients with CLI are warranted.
引用
收藏
页码:58 / 65
页数:8
相关论文
共 23 条
[1]   Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [J].
Baumgartner, I ;
Pieczek, A ;
Manor, O ;
Blair, R ;
Kearney, M ;
Walsh, K ;
Isner, JM .
CIRCULATION, 1998, 97 (12) :1114-1123
[2]   Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial [J].
Bradbury, AW ;
Ruckley, CV ;
Fowkes, FGR ;
Forbes, JF ;
Gillespie, I ;
Adam, DJ ;
Beard, JD ;
Cleveland, T ;
Bell, J ;
Raab, G ;
Storkey, H .
LANCET, 2005, 366 (9501) :1925-1934
[3]   TcPO2 as an accurate predictor of therapy in limb salvage [J].
Bunt, TJ ;
Holloway, GA .
ANNALS OF VASCULAR SURGERY, 1996, 10 (03) :224-227
[4]   Naked plasmid DNA encoding fibroblast growth factor type I for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase I trial [J].
Comerota, AJ ;
Throm, RC ;
Miller, KA ;
Henry, T ;
Chronos, N ;
Laird, J ;
Sequeira, R ;
Kent, CK ;
Bacchetta, M ;
Goldman, C ;
Salenius, JP ;
Schmieder, FA ;
Pilsudski, R .
JOURNAL OF VASCULAR SURGERY, 2002, 35 (05) :930-936
[5]   Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery [J].
Conte, MS ;
Bandyk, DF ;
Clowes, AW ;
Moneta, GL ;
Seely, L ;
Lorenz, TJ ;
Namini, H ;
Hamdan, AD ;
Roddy, SP ;
Belkin, M ;
Berceli, SA ;
DeMasi, RJ ;
Samson, RH ;
Berman, SS .
JOURNAL OF VASCULAR SURGERY, 2006, 43 (04) :742-750
[6]   Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial [J].
Conte, MS ;
Bandyk, DF ;
Clowes, AW ;
Moneta, GL ;
Namini, H ;
Seely, L .
JOURNAL OF VASCULAR SURGERY, 2005, 42 (03) :456-464
[7]  
DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50
[8]  
Dormandy J, 1999, Semin Vasc Surg, V12, P142
[9]   Clinical evidence of angiogenesis after arterial gene transfer of phVEGF(165) in patient with ischaemic limb [J].
Isner, JM ;
Pieczek, A ;
Schainfeld, R ;
Blair, R ;
Haley, L ;
Asahara, T ;
Rosenfield, K ;
Razvi, S ;
Walsh, E ;
Symes, JF .
LANCET, 1996, 348 (9024) :370-374
[10]   Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results [J].
Isner, JM ;
Baumgartner, I ;
Rauh, G ;
Schainfeld, R ;
Blair, R ;
Manor, O ;
Razvi, S ;
Symes, JF .
JOURNAL OF VASCULAR SURGERY, 1998, 28 (06) :964-973